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Abstract
Background: Methylene blue (MB) is a drug with a long history and good safety profile, and with recently-described
features desirable in a treatment for ALS.
Methodology/Principal Findings: We tested oral MB in inbred high-copy number SOD1 G93A mice, at 25 mg/kg/day
beginning at 45 days of age. We measured disease onset, progression, and survival. There was no difference in disease onset
between MB-treated mice and controls, although subgroup analysis showed a modest but statistically significant delay in
disease onset in MB-treated female mice only (control 122610.2 versus MB 129610.0 days). MB-treated mice of both sexes
spent more time in less severe stages of disease, and less time in later, more severe stages of disease. There was a non-
significant trend to longer survival in MB-treated animals (control males reached endpoint at 161614.1 days, versus
166610.0 days for MB-treated animals, and control females reached endpoint at 17166.2 days versus 173613.4 days for
MB-treated animals).
Conclusions/Significance: In spite of a strong theoretical rationale, MB had no significant effects on onset or survival in the
inbred SOD1 G93A mouse model of ALS.
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Introduction
ALS is a fatal disease characterized by progressive weakness of
voluntary muscle. Most cases of ALS are sporadic and without
known cause. Some cases are familial (FALS) and of these, a
minority are associated with known mutation, in genes encoding
SOD1 [1], Alsin [2], Dynactin 1 [3], VAPB [4], angiogenin [5],
TDP43 [6,7], or FUS [8,9] Mutation in genes more commonly
associated with other diseases can rarely present as ALS (eg.
Spastin [10]) as can viral infection (eg. HIV [11] and HTLV [12]).
It is presently unclear how multiple known and unknown triggers
can lead to the same disease phenotype. However, several
pathological mechanisms may be in common, including impaired
axonal transport and reduced trophic support, excitotoxicity,
oxidative stress, mitochondrial dysfunction, inflammation, accel-
erated ageing, and terminally, apoptosis. No intervention in ALS
targeting any of these processes singly has proven successful in
substantially mitigating the disease process. It is possible that these
processes are secondary to a single more fundamental disease
process not yet discovered. Presently, however, ALS may best be
treated with therapies that target multiple points in the disease
cascade.
Methylene Blue is an old drug with several properties of interest
in a potential ALS therapy. MB readily alternates between
reduced and oxidized forms (eg. Wiklund [13]), and it has been
successfully used as a surrogate electron transporter in patients
with impairment of the mitochondrial electron transport chain
(ETC). Thus, MB has a long use in cyanide poisoning, where
Complex IV of the ETC is blocked. Functional defects in ETC
complexes I and IV have been identified in ALS patients [14], and
MB could overcome these deficits.
MB pretreatment reduces brain damage and death following
experimental cardiac arrest in pigs [13]. This effect was attributed
to a reduction in the action of nitric oxide (NO), and decreased
glial activation and lipid peroxidation. MB inhibits nitric oxide
synthase [15]. The synthesis of NO is increased in all studied
SOD1 FALS mutations, an effect not seen with over-expression of
wild-type SOD1 [16], and cellular damage in ALS has been linked
to increased levels of NO (eg. Beal [17], Ferrante [18]).
Similarly, MB protects cultured fibroblasts against H2O2
challenge, an effect attributed in part to the induction of phase-2
antioxidant defense enzymes including NADPH dehydrogenase
quinone 1 and the selenoprotein thioredoxin reductase 1 (Trx1)
[19]. Selenoproteins act as anti-oxidants, in signaling pathways,
and in the maintenance of intracellular REDOX balance [20,21].
Markers of oxidative stress and lipid and protein peroxidation are
all elevated in ALS [22,23], and could be mitigated by MB.
MB reduces pathological microtubule-associated protein (MAP)
tau aggregation [24], and may thereby improve axonal function, a
matter of considerable interest in Alzheimer’s Disease (AD). In a
recent Phase II study of 321 patients with AD, MB slowed disease
progression by 81% [25]. Intraneuronal hyperphosphorylated tau
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impaired axonal transport and axonal dysfunction that character-
ize both sALS and FALS [28,29]. Impairments in retrograde
axonal transport could result in a deficiency of trophic support to
the motor neuron.
Last, MB is one of the few compounds capable of significantly
prolonging lifespan in normal mice and rats, and it does so in a
dose related fashion [30]. The mechanism of this effect is unclear,
but of potential relevance to ALS since it has long been suggested
that ALS is due to an accelerated senescence of motor neurons (eg.
McComas [31]).
Even at the highest dose of MB (25 mg/kg) administered
chronically in the lifespan study in mice and in rats, only minor
toxicity was seen. At usual doses, MB produces few side effects in
humans [19]. Since MB favorably affects several of the pathways
affected in ALS and since it is readily bioavailable to the central
nervous system following oral administration, and since the drug is
already approved for human use, we tested MB in a mouse model
of ALS. Because of concerns of variability in outcome measures
using the standard SOD1 G93A hybrid mouse model raised by
Scott et al [32], we used a more recently developed inbred
(congenic) SOD1 G93A strain for these experiments. We
measured the age at disease onset, disease progression (using a
customized 7-point clinical scale), and age at surrogate death.
Results
Daily oral administration of MB was started at 45 days of age
and continued until death. 26/27 treated animals and 19/20
control animals completed the study according to protocol. One
control group animal and one drug group animal were sacrificed
early at the request of the University veterinarian for reasons not
related to weakness (skin conditions) and censored from the study
as non-ALS deaths. There were no discernable side effects to MB
treatment.
The Kaplan Meier curve for age at disease onset (score 1 on our
disease activity scale) is shown in Figure 1, for all mice, and then
separately by sex. Control mice first showed neurological signs at
121611.5 days (mean6 SD; n=19). This falls between onset
values reported by Wooley et al. [33] (at 142+/210 days) and
those of Hayworth and Gonzalez-Lima [34] (at 100+/22 days
and 91+/22 days for females and males, respectively) in the same
mouse strain. Animals receiving MB showed first signs of disease
slightly later, at 124610.3 days (n=27). This difference was not
significant (log rank p.0.05). However, when stratified by sex, MB
treated female mice showed signs of disease at 129610.0 days
(n=15), compared with 122610.2 days (n=11) in female controls.
This difference was significant (log rank p,0.05). There was no
difference in male mice (11866.9 days MB, n=12 versus
119613.6 days, n=8 control).
The average daily disease activity score for MB and control
mice as a function of age is shown in Figure 2. At most ages, MB-
treated animals had less average disease severity than control mice.
We quantified this by tabulating the average length of time spent
at each score (Table 1). MB treated animals spent more time in the
less severe stages and less time in more severe stages than
untreated animals, although the effect was significant only where
indicated by an asterisk.
MB mice reached endstage (our score 6) at 170612.3 days
(n=27; Figure 3) slightly later than control mice, at 167611.1
days (n=20). This difference was not significant (log rank p.0.05).
When stratified by sex, both males and females treated with MB
survived marginally longer than controls, although the difference
was not significant for either group. (MB females reached endpoint
at 173613.4 days (n=15) and control females at 17166.2 days
(n=12). MB males reached endpoint at 166610.0 days (n=12)
and control males at 161614.1 days (n=8)).
Discussion
MB has multiple properties that should make it an interest-
ing candidate treatment for ALS. As set out above, MB could
overcome the mitochondrial ETC defect seen in ALS, reduce glial
activation and inflammatory responses, reduce oxidative damage,
and improve axonal dysfunction, and even in normal animals, MB
significantly prolongs lifespan.Thus, MB should favourably affect
many of the pathological processes thought to be operative in
ALS, and we held some optimism that it would be successful in an
ALS disease model.
Indeed, SOD1 G93A mice treated with MB did show delayed
disease onset, spend more time in less severe stages and less time in
more severe stages of disease, and die at a later age than control
mice. However, while the effects are minor, often not reaching
statistical significance, and certainly not of the magnitude that we
Figure 1. Kaplan-Meier plots for onset of neurological signs in congenic SOD1 G93A mice. Clinical onset of disease is taken as the age at
which each mouse attained a neurological severity score of 1 (please refer to Materials and Methods for a detailed description of assignment of
neurological scores). The proportion of mice reaching onset over time is shown for all mice (All), females only (F), and in males only (M). Methylene
blue treated (MB) animals received daily 25 mg/kg doses of methylene blue dissolved in JelloH. Vehicle control (Control) animals received unaltered
JelloH cubes.
doi:10.1371/journal.pone.0023141.g001
Effect of Methylene Blue in the SOD1 G93A Mouse
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may be that MB is of minimal utility in ALS, or, it may be that the
model used is flawed.
No single underlying pathogenic mechanism has been forthcom-
ing to explain the multiple pathogenic abnormalities seen in ALS
(impaired axonal transport and reduced trophic support, excitotox-
icity, oxidative stress, mitochondrial dysfunction, inflammation,
accelerated ageing, and terminally, apoptosis), and unfortunately,
all attempts targeting these processessingly have been disappointing
in humans and, even when statistically significant in mouse models,
the effect is always modest. We had hoped that MB, targeting
several of these processes, might be more successful, but this was not
thecase.Thisreinforcesthepossibilitythatsatisfactorytherapymust
await the discovery of more fundamental proximal causes of
pathogenesis.Onepossibilitypresentlyunfoldingisdisordered RNA
processing (eg Kolb [35]), which might underlie many diseases of
the motor neuron, and which might directly or indirectly disrupt
many downstream processes.
Conversely, it is possible that some of the difficulty lies with our
choice of parameters or the SOD1 mouse model itself. We
administered MB at a dose of 25 mg/kg/d. We chose this dose
because it was the highest dose given chronically in the above
referenced longevity study [30], and the dose that produced the
greatest beneficial effect. It is possible that the optimal dose in a
longevity study might differ from an optimal dose in SOD1 mice,
and that a different (larger) dose might have produced greater
benefit. However, the authors of the longevity did consider doses
higher than 25 mg/kg/d, but limiting toxicity was seen in
plreliminary studies, thereby precluding the use of higher doses
in chronic administration.
Also, in the longevity study, MB was administered daily by
gavage. On the advice of our institutional review board and
University veterinarian, we substituted daily oral administration of
MB in flavored gelatin (JelloH), as less stressful to the animals. The
animals enthusiastically consumed the JelloH containing the MB,
and we have no reason to suspect that the JelloH would alter the
Figure 2. Daily average neurological severity score in congenic SOD1 G93A mice. Group average neurological severity scores across the
age from the start of the study to the age at endpoint in all mice (All; NControl=15, NMB=16), females only (F; NControl=10, NMB=10), and males only
(M; NControl=5,NMB=6). Methylene blue treated (MB) animals received daily 25 mg/kg doses of methylene blue dissolved in JelloH. Vehicle control
(Control) animals received unaltered JelloH cubes.
doi:10.1371/journal.pone.0023141.g002
Table 1. Neurological Severity Score in Congenic SOD1 G93A mice: Categorical Analysis of Average Number of Days at Score by
Treatment Group.
1,2
Subjects Parameter Treatment Score 0 Score 1 Score 2 Score 3 Score 4 Score 5 Score 6
All Mean Frequency Control 118.6 25.8 11.67 6.26 3.33 2.6 1.0
Drug 121.4 24.3 14.88 7.19 1.75 1.56 1.0
P value 0.239 0.388 0.014* 0.323 0.005* 0.458 1.0
Female Mean Frequency Control 120.3 23.9 12.3 6.2 3.3 2.4 1.0
Drug 117.3 21.64 13.8 7.91 1.73 2.27 1.0
P value 0.525 0.277 0.336 0.141 0.022* 0.849 1.0
Male Mean Frequency Control 115.2 29.6 10.4 6.4 3.4 3.0 1.0
Drug 116.4 30.0 17.2 5.6 1.8 2.0 1.0
P value 0.860 0.907 0.036* 0.605 0.114 0.316 1.0
1Testing Terms: Scores for Control (unaltered JelloH) and Drug (25 mg/kg methylene blue daily) are given as mean number of days spent within each severity category.
P value lists the probability of obtaining, by chance alone, a value greater than the one computed if the score frequencies are the same for both treatment groups at
group size minus one degree of freedom (test term description taken from the JMPH 7.0.1 Help file).
2Refer to Material and Methods for a detailed description of assignment of neurological scores. Neurological disease severity increases from 0–6. Score 0 is
asymptomatic. Score 6 is surrogate endpoint.
doi:10.1371/journal.pone.0023141.t001
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humans in gelatin capsules [36], and several previous studies have
show that the oral bioavailability of MB is high. Pharmacokinetic
studies in mice and rats show it is well absorbed from the
gastrointestinal tract, readily crosses the blood-brain barrier, and
concentrates in the brain [37–39]. (One hour after duodenal
administration of MB, the brain concentration exceeds the whole
blood concentration by a factor of ten [39]).
However, assuming that there are no major difficulties with
either dose or administration, it is possible that the difficulty lies
with the SOD1 G93A mouse model. This model is subject to large
endpoint variability, as studied by Scott et al [32]. They concluded
that most of the G93A mouse studies to date have been
underpowered, with the reported success of many agents due to
the play of chance and presumably a bias towards reporting
positive results. When they retested compounds reported positive
in previous studies, with greater numbers of animals, matching of
sex and litter, and with control of the transgene copy number,
none of the studies were positive. If true, two solutions to this are
thus possible: one can increase the rigour with which experiments
are undertaken as above, or use a model with less inherent
variability.
We did both. We aimed for a high number of animals per
treatment group, and matched them for sex and litter. Also, we
used an inbred G93A SOD1 mouse model, which should have less
background variability in outcome measures than the hybrid
strain. Indeed, this does seem to be the case. The average standard
deviation in survival reported in the control arms using the hybrid
G93A mouse averages 612 days [40], or perhaps more
meaningfully, 8.8% of the reported lifespan. In our hands, the
standard deviation of the inbred (congenic) controls was 610.6
days, or 5.9% of the reported lifespan. This reduction in variability
should improve reliability and reduce the number of animals
needed for a given power. (Indeed, using these figures, one can
calculate that for customary values (alpha = 0.05 and beta = 0.2),
if 24 mice are recommended for a given effect size in the hybrid
mouse model, then 11 per group would be needed in the inbred
strain, a significant reduction.)
However, we found these animals difficult to use. The inbred B6
dams tended to have poor parenting skills and cannibalized pups
with even minor environmental stress. We lost over 100 pups in
this way, before resorting to surrogate timed-pregnant ICR dams,
which greatly added to the expense of the study. The same power
might be achieved more simply by assuring an adequate number
of the usual SOD1 animals and controlling for copy number, litter
and sex (as suggested by Scott et al. [32]), with equal or less
expense.
It is also possible that the SOD1 G93A mouse suffers more
fundamental difficulties than endpoint variability. Multiple agents
have shown some (albeit modest) benefit in the hybrid G93A
mouse model, yet none have translated to therapeutic success in
humans, and it seems unlikely that chance alone and a bias to
positive reporting could explain this. Another explanation is that
the SOD1 mouse may be a good model for SOD1 FALS, but not
other familial ALS or sporadic disease. The development of
TDP43 mice, which might better reflect most human ALS, might
afford a truer disease model than the SOD1 mouse, and it may be
useful to revisit promising agents minimally successful in SOD1
studies (such as MB), in TDP43 mice.
Materials and Methods
Ethics Statement
All animal experiments and procedures were carried out with
the approval of McMaster University’s Animal Research Ethics
Board, as per the Animal Utilization Protocol 09-11-43.
High-copy SOD1 G93A congenic breeding pairs were obtained
from the Jackson Laboratory (B6.Cg-Tg(SOD1*G93A)1 Gur/J,
stock number, 004435). We maintained the colony by crossing
hemizygous male carriers with inbred wild-type C57BL/6 dams.
These dams tended to cannibalize their pups with even minor
environmental stress, and in consequence we transferred litters
shortly after birth to timed pregnant surrogate ICR dams (Institute
for Cancer Research dams; Charles River, Wilmington, Massa-
chusetts; strain name: Crl:CD1 (ICR), stock number: 022). Mice
were individually housed in the McMaster University Central
Animal Facility in a 12-h light/dark cycle. Food and water were
available ad libitum throughout the study.
Mice were randomly assigned to receive either MB or no MB
(control) at 45 days of age. Allocation was balanced by litter and
sex. MB (Sigma-Aldrich M44907) was dissolved in 3 ml warm
freshly prepared raspberry JelloH solution (at the recommended
Figure 3. Kaplan-Meier plots for survival time in congenic SOD1 G93A mice. Mice are considered moribund and are given a neurological
severity score of 6 at the age at when they can no longer right themselves after 30 seconds of being placed on either side (please refer to Materials
and Methods for a detailed description of assignment of neurological scores). The proportion of mice reaching endpoint over time is shown for all
mice (All), females only (F), and males only (M). Methylene blue treated (MB) animals received daily 25 mg/kg doses of methylene blue dissolved in
JelloH. Vehicle control (Control) animals received unaltered JelloH cubes.
doi:10.1371/journal.pone.0023141.g003
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MB. Liquid JelloH with or without MB was poured into 3 mL
molds, and the solidified cubes were then placed on the bottom of
each animal’s cage on a daily basis. Fresh JelloH was made three
times a week, with each treated animal receiving approximately
25 mg/kg/day MB. Cages were checked each morning to ensure
that the JelloH cubes had been entirely consumed. (They always
were).
All mice were examined daily from 45 days of age to endpoint.
After symptom onset animals were monitored twice daily. Body
weight measurements were monitored periodically prior to onset
of overt symptoms, and weekly afterwards. We used a single 7
point descriptive scale to assess disease progression. To reduce
subjective variability, all assessments were done by a single
examiner (RL).
N 0 Asymptomatic.
N 1 Trembling/shaking of hindlimbs during suspension of mouse
by its tail, and full/partial collapse of leg extension towards
lateral midline. This is the age of onset usually reported [41].
N 2 Impairment of gait with respect to stride length and speed
when mouse is placed on a flat surface.
N 3 Mouse can be placed on its side but rights itself immediately.
N 4 When placed in its side, mouse takes between 2-15 seconds
to right.
N 5 When placed in its side, mouse takes between 16-30 seconds
to right.
N 6 End-stage disease. The mouse is unable to right itself within
30 seconds after being placed in its side. At this point the
animals are euthanized by cervical dislocation.
Kaplan-Meier survival fit analysis with log-rank statistics were
used to analyze the time-to-event measures (onset and survival).
Categorical analysis was used to analyze the daily ordinal
neurological severity score. Differences in score frequencies were
analyzed by Chi Square. (The last scores of euthanized animals
were carried forward.) All statistical tests were carried out using
GraphPad Prism 4.0H, GraphPad Software, Inc., San Diego, CA,
USA and JMPH 8.0, SAS Institute, Inc., SAS Campus Drive,
Cary, NC 27513, USA. Two-tailed p values less than 0.05 were
considered to be statistically significant.
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